Compare AEMD & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEMD | AIXI |
|---|---|---|
| Founded | 1984 | 2001 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 1.7M |
| IPO Year | 2008 | 2022 |
| Metric | AEMD | AIXI |
|---|---|---|
| Price | $0.68 | $1.74 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 196.1K | ★ 383.4K |
| Earning Date | 02-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.84 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $0.08 |
| 52 Week High | $5.89 | $16.28 |
| Indicator | AEMD | AIXI |
|---|---|---|
| Relative Strength Index (RSI) | 24.92 | 27.67 |
| Support Level | $0.64 | $1.72 |
| Resistance Level | $0.83 | $2.35 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 6.47 | 18.03 |
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
XIAO-I Corp operates as a cognitive artificial intelligence company. Using its proprietary intellectual property technologies, the company has developed and commercialized various core technologies, such as Conversational AI, Knowledge Fusion, Intelligence Voice, Hyperautomation, Data Intelligence, Cloud, Intelligent Construction Support, Vision Analysis, Intelligent Hardware Support, and Metaverse. Additionally, it has developed Hua Zang Universal Large Language Model. XIAO-I offers two different product lines: Model as a service (MaaS) and non-MaaS. Key revenue is derived from the non-MaaS product line, which comprises needs assessment, solution design and architecture planning, development and configuration, deployment, and implementation of non-model (mainly cloud platform) products.